Ivarmacitinib to prevent GVHD after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if a drug called Ivarmacitinib can prevent graft-versus-host disease (a common complication where donor cells attack your body) after a stem cell transplant from a half-matched donor. It is for people with certain blood cancers who are about to receive a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer such as AML, ALL, CML, MDS, non-Hodgkin lymphoma, or Hodgkin lymphoma.
- You are scheduled to receive a stem cell transplant from a half-matched donor.
- You have not had any previous treatment for your condition, including light therapy.
- You are in good enough health to undergo a transplant (e.g., able to care for yourself).
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
This trial tests a drug called Ivarmacitinib for people whose solid tumors stopped responding to immunotherapy due to side effects. It aims to see if Ivarmacitinib can help control the tumor while managing those side effects.
This trial tests whether the drug gecacitinib can help prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant in people with myelofibrosis, a rare bone marrow disorder.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests a new drug called axatilimab, given alongside standard care, to help prevent graft-versus-host disease after a stem cell transplant for blood cancer. It may be an option for people who are planning a first transplant from a matched donor.
Hear when a new aGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.